Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Paris, Ile-De-France and currently employs 15 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.
Follow-Up Questions
Advicenne SA의 CEO는 누구입니까?
Mr. Didier Laurens은 2021부터 회사에 합류한 Advicenne SA의 Chief Executive Officer입니다.
ADVVF 주식의 가격 성능은 어떻습니까?
ADVVF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Advicenne SA의 주요 사업 주제나 업종은 무엇입니까?
Advicenne SA은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
Advicenne SA의 시가총액은 얼마입니까?
Advicenne SA의 현재 시가총액은 $NaN입니다
Advicenne SA는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 Advicenne SA에 대한 분석 평가를 실시했으며, 이는 3명의 강력한 매수, 5명의 매수, 1명의 보유, 0명의 매도, 그리고 3명의 강력한 매도를 포함합니다